IBTA e-News June 2017 released

By 1st July 2017 August 1st, 2017 News archive
[30 June 2017] The IBTA's monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.

You can read the IBTA e-News June 2017 edition in full online here.

Some of the highlights from this month's include:

  • The US Food and Drug Administration (FDA) has approved Gleolan (5-aminolevulinic acid hydrochloride, also known as 'Gliolan') for use to improve the visualisation of  grade 3 or 4 glioma tumour tissue during surgery.
  • A study published in the Journal of Neuro-Oncology has found that a class of blood pressure drugs (ASI) appear to improve survival in recurrent glioblastoma patients being treated with chemotherapy and/or the antiangiogenic agent bevacizumab (Avastin).
  • Published in Nature Neuroscience, animal experiments have revealed that a combination of existing medicines (erlotinib and thalidomide) traditionally used separately to treat lung cancer and arthritis can destroy glioblastoma tumours.
  • A study has shown that changes in immune activity appear in the blood several years before symptoms of a brain tumour arises, suggesting that it may be possible to screen for glioma.
  • Results of a phase 2 clinical trial suggest that the drug selumetinib appears to be safe and effective as a therapy in recurrent or refractory low-grade glioma in children.
  • The Hospital for Sick Children (SickKids) in Toronto, Canada, has announced that one of the organisation’s brain tumour research projects is to receive CAD$4.8 million in Translational Research Initiatives (TRIs) funding over two years to examine the cellular and genetic differences of paediatric and adult brain tumours.
  • Novocure has announced that the first patient has been enrolled in the RTOG(Radiation Therapy Oncology Group) Foundation’s phase 2 pilot trial testing Optune together with bevacizumab (Avastin) in glioblastoma patients experiencing recurrence or progression after bevacizumab treatment.
  • Currently recruiting is a phase 2, open-label, non-randomised multi-center clinical trial (NCT02034110) of the oral drugs dabrafenib and trametinib for adults with rare cancers, which includes both high- and low-grade glioma (WHO Grades 1 - 4). Further information on the trial can be found here (Clinicaltrials.gov website).

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.